Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells $123,200.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 20,000 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at approximately $4,697,960.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Christopher Gibson also recently made the following trade(s):

• On Wednesday, September 4th, Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.04, for a total transaction of $120,800.00.
• On Wednesday, August 7th, Christopher Gibson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.10, for a total value of $213,000.00.
• On Wednesday, July 10th, Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.48, for a total value of $374,000.00.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $6.11 on Monday. The firm’s 50 day moving average is $6.83 and its two-hundred day moving average is $8.04. The firm has a market capitalization of $1.72 billion, a P/E ratio of -3.82 and a beta of 0.80. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.97 and a 52 week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same period in the previous year, the firm earned ($0.38) EPS. The firm’s revenue was up 30.9% on a year-over-year basis. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Handelsbanken Fonder AB lifted its stake in shares of Recursion Pharmaceuticals by 33.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 69,500 shares of the company’s stock worth $458,000 after acquiring an additional 17,400 shares during the period. SG Americas Securities LLC raised its holdings in Recursion Pharmaceuticals by 249.0% during the third quarter. SG Americas Securities LLC now owns 89,325 shares of the company’s stock worth $589,000 after purchasing an additional 63,727 shares in the last quarter. Ghisallo Capital Management LLC acquired a new stake in Recursion Pharmaceuticals in the second quarter worth approximately $8,250,000. Perceptive Advisors LLC bought a new position in Recursion Pharmaceuticals during the 2nd quarter valued at $5,769,000. Finally, Algert Global LLC acquired a new position in shares of Recursion Pharmaceuticals during the 2nd quarter valued at $129,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

RXRX has been the topic of a number of research reports. KeyCorp dropped their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Needham & Company LLC decreased their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Jefferies Financial Group dropped their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Finally, Leerink Partners cut their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.